Ajanta Pharma Limited

Ajanta Pharma Limited (APL) (BSE: 532331 | NSE: AJANTPHARM) is an Indian multinational, marketing pharmaceutical formulations worldwide, with its head quarter in Mumbai. It is a fully integrated company having presence in the entire value chain from R&D to API to Formulation to Brands. It has presence in fast growing specialty therapeutic segments of Cardiology, Dermatology, Ophthalmology, apart from serving many other main line therapeutic segments like Anti-malarial, Premium anti-biotic, Anti-allergy etc. With its mission of 'Serving Global Health Care Needs Worldwide', Ajanta Pharma has been consistently providing affordable and quality medicines to the patients in different parts of the World. Established in 1973, Ajanta Pharma has rich experience of 39 years in the pharma industry with impeccable record of quality. The company has always been pioneering in its efforts to service the ailing mankind. It has unique advantage of launching innovative R&D products in the market ahead of competition, many of them being first of its kind. Ajanta has built an outstanding brand image in the emerging markets of Asia, Africa and Latin America and now entered the developed market of USA. Ajanta’s export business is entirely driven by its own brands. The product basket varies from country to country to make it a specialty business in each of the markets and hence therapeutic segments covered in exports are wider than the domestic market. Currently company’s products are available in more than 25 countries and in many of the markets company’s products are among the leaders in the segment. APL currently has 2 ANDA’s approved by US FDA and 9 more ANDA’s are awaiting approval. Company plans to file 5-6 ANDA’s every year with an objective of strengthening its presence in the US market. APL also has been granted marketing authorization (MA) for Sildenafil Citrate Tablets (kamagra) 50mg & 100mg in UK, Germany, France, The Netherlands, Denmark, Ireland, Hungary, Portugal and Bulgaria and awaiting the MA in Italy, Spain, Greece, Belgium and Poland which is expected shortly. The company has applied for the product’s registration in 14 EU countries under the DCP (Decentralized Procedure), pertaining to which it has received approval from these 9 countries. It proposes to launch this product in these EU countries after expiry of patent regime of this product. APL has in-house R&D centre 'Advent' recognized by DSIR, Govt. of India, which has state-of-the-art facilities for product development and process development. The research centre has built strong capabilities for developing Generic formulations and process chemistry. Generic formulation development include value added technology platforms such as sustained release, control release, extended release, oral dosage to liquids, ointments and eye drops.